Impact of patient’s clinical features on the recurring lungmetastases of breast cancer

Saricam, Murat

doi:10.5455/annalsmedres.2020.05.470

Impact of patient’s clinical features on the recurring lungmetastases of breast cancer

Murat SARIÇAM (Tekirdağ Namık Kemal Üniversitesi, Tıp Fakültesi, Göğüs Cerrahisi Anabilim Dalı, Tekirdağ, Türkiye)

Annals of Medical Research

0 0

Yıl: 2021 Cilt: 28 Sayı: 6 Sayfa Aralığı: 1253 - 1256 Metin Dili: İngilizce DOI: 10.5455/annalsmedres.2020.05.470 İndeks Tarihi: 26-11-2021

Impact of patient’s clinical features on the recurring lungmetastases of breast cancer

Öz:

Aim: The aim of this study was to investigate the clinical features affecting on the recurrence of lung metastases of breast cancer. Materials and Methods: Data of 92 patients who had undergone pulmonary metastasectomy of breast cancer were examined interms of recurrence, age, type of primary breast cancer, disease free interval (DFI), PET/CT findings, side of metastasectomy andnumber of resected lung metastases. Results: Solitary and unilateral pulmonary metastases presenting lower SUV following longer period of DFI were less involved inrecurrence whereas invasive lobular and inflammatory carcinomas were more inclined to develop relapsing lung metastases. Agewas not a risk factor for recurrence. Conclusion: Identifying high risk patients for recurrence contributes to prevention of repeating and excessive surgeries.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Diğer Erişim Türü: Erişime Açık

1. Jin X, Mu P. Targeting breast cancer metastasis. Breast Cancer 2015;9:23-34.
2. Redig AJ, McAllister SS. Breast cancer as a systemic disease: a view of metastasis. J Intern Med 2013;274:113-26.
3. Scully OJ, Bay B, Yip G, Yu Y. Breast cancer metastasis. Can Gen Prot 2012;9:311-20.
4. Sledge GW. Curing metastatic breast cancer. J Onc Prac 2016;12:11-3.
5. Jyotsana N, Zhang Z, Himmel LE, et al. Minimal dosing of leukocyte targeting trail decreases triple-negative breast cancer metastasis followingtumor resection. Sci Adv 2019;5:1-11.
6. Karagiannis GS, Goswami S, Jones JG, et al. Signatures of breast cancer metastasis at a glance. J Cell Sci 2016;129:1751-8.
7. Jin L, Han B, Siegel E, et al. Breast cancer lung metastasis: molecular biology and therapeutic implications. Canc Bio Ther 2018;19:858-68.
8. Xiao W, Zheng S, Liu P, et al. Risk factors and survival outcomes in patients with breast cancer and lung metastasis: a population-based study. Cancer Medicine 2018;7:922-30.
9. Shoji M, Qian WP, Nagaraju GP, et al. Inhibition of breast cancer metastasis to the lungs with UBS109. Oncotarget 2018;9:36102-9.
10. Lu J, Steeg PS, Price JE, et al. Breast cancer metastasis: challenges and opportunities. Cancer Res 2009;69:4951-3.
11. Kycler W, Laski P. Surgical approach to pulmonary metastases from breast cancer. Breast J 2012;18:52- 7.
12. Molnar IA, Molnar BA, Vizkeleti L, et al. Breast carcinoma subtypes show different patterns of metastatic behavior. Virchows Arch 2017;470:275-83.
13. Brandt J, Garne JP , Tengrup I, et al. Age at diagnosis in relation to survival following breast cancer: a cohort study. World J Surg Oncol 2015;13:33-44.
14. Kim S, Han B, Kim E, et al. Breast cancer detected at screening US: survival rates and clinical-pathologic and imaging factors sssociated with recurrence. Radiology 2017;284:354-64.
15. Randhawa J, Park T, Malhotra A, et al. Two cases of possible remission in metastatic triple-negative breast cancer. JCSO 2017;15:176-8.
16. Howlader N, Cronin KA, Kurian AW, et al. Differences in breast cancer survival by molecular subtypes in the United States. Cancer Epid Biomark Prev 2018.
17. Orevi M, Freedman N, Tahover E, et al. Is 18F-FDG PET/CT an accurate tool for identifying metastases of lobular breast cancer? Acta Oncol 2016;55:244-7.
18. Taalab K, Abutaleb AS, Moftah SG, et al. The diagnostic value of PET/CT in breast cancer recurrence and metastases. Egyptian J Nucl Med 2017;15:37-51.
19. Ulaner GA. PET/CT for patients with breast cancer: Where is the clinical impact? Am J Roentgenol 2019;213:254-65.
20. Caresia A, Garcia P, Vicente AM, et al. 18F-FDG PET/CT in breast cancer: Evidence-based recommendations in initial staging. Tumor Biol 2017;39:1010-8.
21. Hallifax RJ, Talwar A, Wrightson JM, et al. State-ofthe-art: Radiological investigation of pleural disease. Respiratory Medicine 2017;124:88-99.
22. Hong S, Li J, Wang S. 18FDG PET-CT for diagnosis of distant metastases in breast cancer patients. A metaanalysis. Surg Oncol. 2013;22:139-43.
23. Bernsdorf M, Berthelsen AK, Wielenga VT, et al. Preoperative PET/CT in early-stage breast cancer. Annal Oncol. 2012;23:2277-82.
24. Dong G, Wang D , Liang X , et al. Factors related to survival rates for breast cancer patients. Int J Clin Exp Med. 2014;7:3719-24.
25. Nishimura R, Osako T, Nishiyama Y, et al. Evaluation of factors related to late recurrence, later than 10 years after the initial treatment in primary breast cancer. Oncology 2013;85:100-10.

APA	Saricam M (2021). Impact of patient’s clinical features on the recurring lungmetastases of breast cancer. , 1253 - 1256. 10.5455/annalsmedres.2020.05.470
Chicago	Saricam Murat Impact of patient’s clinical features on the recurring lungmetastases of breast cancer. (2021): 1253 - 1256. 10.5455/annalsmedres.2020.05.470
MLA	Saricam Murat Impact of patient’s clinical features on the recurring lungmetastases of breast cancer. , 2021, ss.1253 - 1256. 10.5455/annalsmedres.2020.05.470
AMA	Saricam M Impact of patient’s clinical features on the recurring lungmetastases of breast cancer. . 2021; 1253 - 1256. 10.5455/annalsmedres.2020.05.470
Vancouver	Saricam M Impact of patient’s clinical features on the recurring lungmetastases of breast cancer. . 2021; 1253 - 1256. 10.5455/annalsmedres.2020.05.470
IEEE	Saricam M "Impact of patient’s clinical features on the recurring lungmetastases of breast cancer." , ss.1253 - 1256, 2021. 10.5455/annalsmedres.2020.05.470
ISNAD	Saricam, Murat. "Impact of patient’s clinical features on the recurring lungmetastases of breast cancer". (2021), 1253-1256. https://doi.org/10.5455/annalsmedres.2020.05.470

APA	Saricam M (2021). Impact of patient’s clinical features on the recurring lungmetastases of breast cancer. Annals of Medical Research, 28(6), 1253 - 1256. 10.5455/annalsmedres.2020.05.470
Chicago	Saricam Murat Impact of patient’s clinical features on the recurring lungmetastases of breast cancer. Annals of Medical Research 28, no.6 (2021): 1253 - 1256. 10.5455/annalsmedres.2020.05.470
MLA	Saricam Murat Impact of patient’s clinical features on the recurring lungmetastases of breast cancer. Annals of Medical Research, vol.28, no.6, 2021, ss.1253 - 1256. 10.5455/annalsmedres.2020.05.470
AMA	Saricam M Impact of patient’s clinical features on the recurring lungmetastases of breast cancer. Annals of Medical Research. 2021; 28(6): 1253 - 1256. 10.5455/annalsmedres.2020.05.470
Vancouver	Saricam M Impact of patient’s clinical features on the recurring lungmetastases of breast cancer. Annals of Medical Research. 2021; 28(6): 1253 - 1256. 10.5455/annalsmedres.2020.05.470
IEEE	Saricam M "Impact of patient’s clinical features on the recurring lungmetastases of breast cancer." Annals of Medical Research, 28, ss.1253 - 1256, 2021. 10.5455/annalsmedres.2020.05.470
ISNAD	Saricam, Murat. "Impact of patient’s clinical features on the recurring lungmetastases of breast cancer". Annals of Medical Research 28/6 (2021), 1253-1256. https://doi.org/10.5455/annalsmedres.2020.05.470